The slip
PARKINSON RECEIPTno. 17259
01 Nov 2026, 10:47 UTCdopamine neurons, braak
predictionVPS36 in dopamine neurons tracks Braak Lewy-body stage
registeredce61406090fddf08
discovery-0.08 p=0.842 n=9
replication-0.31 p=0.411 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.08, p 0.842)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT36b3a335fcb4d90179428f81…
follows b54e44d88a21…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 17259: VPS36 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.532, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.13 (p 0.621, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.741, n 18). could be the mix.
- skeptic
- leave-one-out range -0.27 to -0.03, sign flips 0; without severely affected donors -0.16 (p 0.532, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.61 (p 0.0069, n 18) vs -0.16 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VPS36 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up VPS36 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 1.3e-4)